This has been referenced in several of the MPN forums in the last several years. CALR is the only driver mutation that causes a change in the proteins on the wall of hematopoietic stem cells. That allows for the potential of a vaccine that can identify the mutated cells and attack them. The short version is that it is a promising treatment option, but it is too soon to be sure. That is why the clinical trials are so important.

It is a phase 1 study. The MPN specialist I am seeing for the trial (not my regular physician) seems to believe it is promising. I am receiving the vaccine regimen but not the vaccine regimen in combination with a study drug that half of the participants are getting.

I am in a different vaccine trial for ET, mine being Calr.

Hi Cindy!
Which phase dear? Is it promising? When can we expect the vaccine to be approved?
I am Calr ET too